Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study. (Q64900205)

30 June 2019

http://europepmc.org/abstract/MED/16151606

title

Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study. (English)

1 reference

30 June 2019

http://europepmc.org/abstract/MED/16151606

7

Caren Gundberg

1 reference

30 June 2019

http://europepmc.org/abstract/MED/16151606

Bruce W. Hollis

6

object named as

Bruce W Hollis

1 reference

30 June 2019

http://europepmc.org/abstract/MED/16151606

author name string

Mara J Horwitz

1

1 reference

30 June 2019

http://europepmc.org/abstract/MED/16151606

Mary Beth Tedesco

2

1 reference

30 June 2019

http://europepmc.org/abstract/MED/16151606

Susan M Sereika

3

1 reference

30 June 2019

http://europepmc.org/abstract/MED/16151606

Adolfo Garcia-Ocaña

4

1 reference

30 June 2019

http://europepmc.org/abstract/MED/16151606

Alessandro Bisello

5

1 reference

30 June 2019

http://europepmc.org/abstract/MED/16151606

Andrew F Stewart

8

1 reference

30 June 2019

http://europepmc.org/abstract/MED/16151606

language of work or name

English

0 references

publication date

7 September 2005

1 reference

30 June 2019

http://europepmc.org/abstract/MED/16151606

published in

Osteoporosis International

1 reference

30 June 2019

http://europepmc.org/abstract/MED/16151606

volume

17

1 reference

30 June 2019

http://europepmc.org/abstract/MED/16151606

issue

2

1 reference

30 June 2019

http://europepmc.org/abstract/MED/16151606

page(s)

225-230

1 reference

30 June 2019

http://europepmc.org/abstract/MED/16151606

cites work

Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunte

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Time- and dose-related biphasic effects of synthetic bovine parathyroid hormone fragment 1-34 on urinary cation excretion

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Hemodynamic Effects of Parathyroid Hormone-Related Peptide-(1–34) in Humans1

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

A comparison of the in vivo biochemical responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Rapid development of renal resistance to low doses of synthetic bovine parathyroid hormone fragment 1-34. Dissociation of urinary cyclic adenosine monophosphate, phosphaturic, and calciuric responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Parathyroid hormone-related protein-(1--36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Parathyroid hormone as a smooth muscle relaxant

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Coming to grips with bone loss

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Clinical review 123: Anabolic therapy for osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Parathyroid hormone-related protein: an essential physiological regulator of adult bone mass

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Parathyroid Hormone plus Alendronate — A Combination That Does Not Add Up

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

Parathyroid hormone-related protein as a cardiovascular regulatory peptide

1 reference

https://pubmed.ncbi.nlm.nih.gov/16151606

12 December 2020

10.1007/S00198-005-1976-3

Identifiers

DOI

1 reference

30 June 2019

http://europepmc.org/abstract/MED/16151606

Dimensions Publication ID

1047476521

0 references

1 reference

30 June 2019